Article thumbnail

Thalassemia and Venous Thromboembolism

By Julien Succar, Khaled M. Musallam and Ali T. Taher

Abstract

Although the life expectancy of thalassemia patients has markedly improved over the last few decades, patients still suffer from many complications of this congenital disease. The presence of a high incidence of thromboembolic events, mainly in thalassemia intermedia, has led to the identification of a hypercoagulable state in these patients. In this review, the molecular and cellular mechanisms leading to hypercoagulability in thalassemia are highlighted, with a special focus on thalassemia intermedia being the group with the highest incidence of thrombotic events as compared to other types of thalassemia. Clinical experience and available clues on optimal management are also discussed

Topics: Perspectives
Publisher: Università Cattolica del Sacro Cuore
OAI identifier: oai:pubmedcentral.nih.gov:3113280
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). Age-related complications in treatment-naive patients with thalassaemia intermedia.
  2. (1995). Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost
  3. (2010). Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia.
  4. (2005). Coagulation and splenectomy: an overview.
  5. (2008). Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica
  6. (1999). Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells.
  7. (1996). Enhanced aggregability of red blood cells of beta-thalassemia major patients.
  8. (1955). Genetic and biochemical studies of intermediate types of Cooley's anaemia.
  9. (2009). Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in plateletpoor plasma. Haematologica
  10. (2003). In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy.
  11. (1991). In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood
  12. (1997). In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with betathalassaemia major.
  13. (2003). Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost
  14. (2002). Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia.
  15. (1981). Increased circulating platelet aggregates in thalassaemia.
  16. (1996). Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb Haemost
  17. (2001). Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes.
  18. (1999). MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease.
  19. (1978). Nonspecific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity.
  20. (2010). Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood
  21. (1993). PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients.
  22. (1993). Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes.
  23. (1989). Platelet survival in patients with beta-thalassemia.
  24. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health 1997; 28 Suppl 3:141-148A.
  25. (2006). Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost
  26. (1992). Pulmonary microthromboemboli in thalassemic cases.
  27. (2010). Redefining thalassemia as a hypercoagulable state.
  28. (2002). Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients.
  29. (2010). Splenectomy and thrombosis: the case of Mediterr J Hematol Infect Dis 2011; 3: Open Journal System thalassemia intermedia. J Thromb Haemost
  30. (1989). Survival and causes of death in thalassaemia major. Lancet
  31. (2004). Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica
  32. (2008). Thalassemia and hypercoagulability. Blood Rev
  33. (2006). Thalassemia intermedia: revisited. Blood Cells Mol Dis
  34. (2004). The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisyle-grand)
  35. (2001). The thalassaemia syndromes. 4th ed.
  36. (1998). Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol
  37. (2001). Thrombophilia in thalassemia major patients: analysis of genetic predisposing factors. Haematologica
  38. (2000). Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia.